Lexeo Therapeutics (LXEO) EBITDA (2022 - 2026)

Lexeo Therapeutics has disclosed EBITDA across 5 years of filings, most recently posting -$20.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$20.5 million, up 37.05% year-over-year; the trailing twelve-month figure through Mar 2026 was -$91.4 million (down 230.09% YoY), and the FY2025 annual result was -$99.7 million, down 1.25% from the prior year.
• EBITDA came in at -$20.5 million for Q1 2026 at Lexeo Therapeutics, up from -$23.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $57.7 million in Q4 2024 to a low of -$32.6 million in Q1 2025.
• The 5-year median for EBITDA is -$20.5 million (2026), against an average of -$16.1 million.
• Across the five-year window, EBITDA surged 485.42% in 2024 and sank 140.05% in 2025, its largest moves.
• Lexeo Therapeutics' EBITDA stood at -$15.2 million in 2022, then gained by 1.47% to -$15.0 million in 2023, then soared by 485.42% to $57.7 million in 2024, then tumbled by 140.05% to -$23.1 million in 2025, then rose by 11.2% to -$20.5 million in 2026.
• The last three EBITDA figures came in at -$20.5 million (Q1 2026), -$23.1 million (Q4 2025), and -$21.6 million (Q3 2025), per Business Quant data.